Detailed Research: Economic Perspectives on ABIOMED, NetScout, FTI Consulting, Enova International, Sturm, Ruger, and IDEX — What Drives Growth in Today's Competitive Landscape

Jan 08, 2018 12:50 pm UTC| Business

NEW YORK, Jan. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ABIOMED, Inc....

New Research Coverage Highlights ConnectOne, Rockwell Medical, Accelerate Diagnostics, Eleven Biotherapeutics, Renasant, and Natera — Consolidated Revenues, Company Growth, and Expectations for 2018

Jan 08, 2018 12:40 pm UTC| Business

NEW YORK, Jan. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ConnectOne...

Factors of Influence in 2018, Key Indicators and Opportunity within Insys Therapeutics, LGI Homes, Steelcase, AtriCure, Alliance Holdings GP, and Digital Turbine — New Research Emphasizes Economic Growth

Jan 08, 2018 12:35 pm UTC| Business

NEW YORK, Jan. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Insys...

Comvest Credit Partners Announces Investment in Cash 4 You Corp.

Jan 08, 2018 12:31 pm UTC| Business

WEST PALM BEACH, Fla., Jan. 08, 2018 -- Comvest Credit Partners (“Comvest”) acted as Administrative Agent and Lender for a C$40 million Senior Term Loan to Cash 4 You Corp. (“Cash 4 You” or the “Company”), a Canadian...

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention

Jan 08, 2018 12:31 pm UTC| Business

-- Highly statistically significant results with rapid prevention beginning Day One, 50%, 75%, 100% responder rates by month one sustained for three months -- -- 15% of patients had no migraines for a full three months...

TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies

Jan 08, 2018 12:31 pm UTC| Business

US IND Filing Expected in the First Half of 2018 Hengrui is Eligible to Receive Collaboration and Licensing Payments of Approximately $350MM, in Addition to Royalties on Future Sales NEW YORK and SHANGHAI, China, Jan. ...

Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance

Jan 08, 2018 12:31 pm UTC| Business

            310+ People with Fabry Disease Treated with Reimbursed Galafold® at YE17 FY18 Galafold Revenue Guidance of $75M-$85M Regulatory Agreement on Comparability of 1,000L Scale Engineering Material for Pompe ...